Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

baxter lithuania, uab - natrio chloridas/kalio chloridas/magnio chloridas heksahidratas/natrio acetatas trihidratas/natrio gliukonatas - infuzinis tirpalas - 5,26 g/0,37 g/0,3 g/3,68 g/5,02 g/1000 ml - electrolytes

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - natrio chloridas/kalio chloridas/magnio chloridas heksahidratas/kalcio chloridas dihidratas/natrio acetatas trihidratas/l-obuolių rūgštis - infuzinis tirpalas - 6,8 g/0,3 g/0,2 g/0,37 g/3,27 g/0,67 g/1000 ml - electrolytes

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi deutschland gmbh - poli(0-2-hidroksietil) krakmolas/natrio acetatas trihidratas/natrio chloridas/kalio chloridas/magnio chloridas heksahidratas - infuzinis tirpalas - 60 g/4,63 g/6,02 g/0,3 g/0,3 g/1000 ml - hydroxyethylstarch

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - Želatina/natrio chloridas/natrio acetatas trihidratas/kalio chloridas/kalcio chloridas dihidratas/magnio chloridas heksahidratas - infuzinis tirpalas - 40 g/5,55 g/3,27 g/0,3 g/0,15 g/0,2 g/1000 ml - gelatin agents

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia ingen pharma - lidokaino hidrochloridas/amilmetakrezolis/2,4-dichlorobenzilo alkoholis - kietosios pastilės - 2 mg/0,6 mg/1,2 mg - various

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide

Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihipertenzinių vaistų, - plaučių arterinės hipertenzijos (pah) gydymas, siekiant pagerinti pratimų pajėgumus ir simptomus pacientams, sergantiems pso funkcine iii klase. efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. kai kurie patobulinimai taip pat buvo įrodyta, pacientams, sergantiems pah, kurie funkcinė klasė ii. tracleer taip pat nurodė sumažinti naujų skaitmeninių opų pacientams, sergantiems sistemine skleroze ir nuolat skaitmeninis opa ligos.

Den europeiske union - litauisk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antinavikiniai vaistai - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Den europeiske union - litauisk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antinavikiniai vaistai - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Den europeiske union - litauisk - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresantai - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).